Türker, YasinEkinözü, İsmailAytekin, SedaTürker, YaseminBaşar, CengizBaltacı, DavutKaya, Ertuğrul2020-04-302020-04-3020171076-02961938-2723https://doi.org/10.1177/1076029615600792https://hdl.handle.net/20.500.12684/3149Kaya, Ertugrul/0000-0003-0081-682XWOS: 000394912700008PubMed: 26276685We hypothesized that patients taking warfarin require frequent hospital follow-up and they are at higher risk for complications, so the incidence of depression and anxiety is higher in patients with atrial fibrillation (AF) in the period of taking warfarin compared to the period of taking dabigatran. Fifty patients having AF without valvular diseases under treatment of warfarin in whom a transition to dabigatran was planned were consecutively enrolled in this study and followed up prospectively between July 2013 and July 2014. All patients completed Beck Depression Inventory and Hamilton Anxiety Scale (HAS) at the initiation of study and 6 months after initiation of study. Of the patients enrolled in the study, age, gender, smoking status, and comorbidities were questioned. A total of 50 patients (28 women; mean age 74.6 +/- 8.7 years) treated with warfarin in whom a transition to dabigatran was planned were included. Basal mean value of BDS (15.6 +/- 7.8 vs 11.5 +/- 4.8, P < .001) and HAS (16.8 +/- 10.4 vs 12.6 +/- 8.1, P < 0.001) was significantly higher in patients when they used warfarin than when they switched to dabigatran. In categorical analysis, frequency of patients with depression (mild, moderate, and severe) was significantly higher in period of warfarin use than after dabigatran transition (n = 24, 48% vs n = 14, 28%, P = .039). Our study demonstrates that patients with nonvalvular AF under treatment of dabigatran had lower BDS and HAS scores compared to warfarin. These findings suggest that dabigatran may increase quality of life and decrease morbidity and mortality due to reduction in anxiety and depression.en10.1177/1076029615600792info:eu-repo/semantics/openAccessanxietydepressionwarfarindabigatranArticle232164167WOS:000394912700008Q2Q3